Who are in the management team of Artemis Medicare?

As of March 2023, the management team of Artemis Medicare includes Deepa Gopalan Wadhwa, Sunil Tandon, Shalini Kanwar Chand, Onkar S Kanwar (Chairman), Neeraj Kanwar, S Narayan, Nirmal Kumar Ganguly, Sanjaya Baru, Sanjib Sen, Devlina Chakravarty (Managing Director), and Poonam Makkar (Company Secretary). The team comprises a mix of independent directors and company executives.

As of March 2023, the management team of Artemis Medicare includes the following individuals:<BR><BR>1. Deepa Gopalan Wadhwa - Independent Director<BR>2. Sunil Tandon - Independent Director<BR>3. Shalini Kanwar Chand - Director<BR>4. Onkar S Kanwar - Chairman & Director<BR>5. Neeraj Kanwar - Director<BR>6. S Narayan - Independent Director<BR>7. Nirmal Kumar Ganguly - Director<BR>8. Sanjaya Baru - Independent Director<BR>9. Sanjib Sen - Independent Director<BR>10. Devlina Chakravarty - Managing Director<BR>11. Poonam Makkar - Company Secretary & Compliance Officer<BR><BR>This diverse team includes a mix of independent directors and company executives, contributing to the governance and management of Artemis Medicare.

When is the next results date for Artemis Medicare?

No Upcoming Board Meetings

Has Artemis Medicare declared dividend?

Artemis Medicare Services Ltd has declared a 45% dividend, amounting to 0.45 per share, with an ex-date of July 5, 2024. Despite a recent 6-month price return of -21.46%, the company has shown strong total returns over longer periods, particularly a 1358.88% total return over the past 5 years.

Artemis Medicare Services Ltd has declared a 45% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.46%, with a dividend return of 0%, resulting in a total return of -21.46%.<BR><BR>Over the past year, the price return was 53.3%, with a dividend return of 0.25%, leading to a total return of 53.55%.<BR><BR>In the 2-year period, the price return was 205.4%, with a dividend return of 0.88%, culminating in a total return of 206.28%.<BR><BR>For the 3-year period, the price return was 472.81%, with a dividend return of 2.26%, resulting in a total return of 475.07%.<BR><BR>In the last 4 years, the price return was 860.16%, with a dividend return of 2.87%, leading to a total return of 863.03%.<BR><BR>Finally, over the past 5 years, the price return was 1353.8%, with a dividend return of 5.08%, resulting in a total return of 1358.88%.<BR><BR>Overall, Artemis Medicare has shown significant total returns over the years, particularly in the longer term, despite a recent negative price return in the last 6 months. The declared dividend indicates a commitment to returning value to shareholders, although the yield remains relatively low.

Who are the peers of the Artemis Medicare?

Peers of Artemis Medicare include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Dr Agarwal's Eye, Shalby, GPT Healthcare, and KMC Speciality. In terms of performance, Fortis Health leads with a 1-year return of 60.01%, while Artemis Medicare has a return of 55.32%.

Peers: The peers of Artemis Medicare are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Dr Agarwal's Eye, Shalby, GPT Healthcare, and KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, and GPT Healthcare, while Average management risk is found at Fortis Health., Dr Agarwal's Eye, Shalby, and KMC Speciality, and the rest. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health., Narayana Hrudaya, and the rest, while Average growth is seen at Global Health, Dr Agarwal's Eye, and Shalby, with Below Average growth at Artemis Medicare and KMC Speciality. Capital Structure is Excellent at Max Healthcare and GPT Healthcare, Good at Fortis Health. and Shalby, Average at Artemis Medicare, and Average at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 60.01%, while the lowest is Shalby at -28.92%. Artemis Medicare's 1-year return of 55.32% is significantly higher than Shalby's but lower than Fortis Health.'s. Additionally, Global Health, Shalby, GPT Healthcare, and KMC Speciality have negative six-month returns.

What does Artemis Medicare do?

Artemis Medicare Services Ltd operates multi-specialty hospitals and was established in 2004, with its first hospital opening in 2007. As of March 2025, it reported net sales of ₹2,399 Cr and a net profit of ₹230 Cr, with a market cap of ₹3,487 Cr.

Overview: <BR>Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals within the hospital industry and falls under the small-cap market category.<BR><BR>History: <BR>The company was incorporated on May 18, 2004, and commenced commercial operations by establishing Artemis Hospital (formerly Artemis Health Institute) in Gurugram on July 16, 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2,399 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 230 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 3,487 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 42.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.18% <BR>Debt-Equity: -0.13 <BR>Return on Equity: 9.86% <BR>Price-to-Book: 4.21 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Artemis Medicare?

The top shareholder of Artemis Medicare is Constructive Finance Private Limited, holding 67.17%. Other significant shareholders include the Governor of Kerala at 4.91%, mutual funds at 1.96%, foreign institutional investors at 0.31%, and individual investors with a collective stake of 12.86%.

The top shareholders of Artemis Medicare primarily include the promoters, with Constructive Finance Private Limited holding the highest stake at 67.17%. The promoters collectively have a significant portion of the shares, with 44.53% of their holdings pledged. In terms of public shareholders, the Governor of Kerala is the largest, holding 4.91%. Additionally, mutual funds hold 1.96% across four schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.31% through 24 different entities. Individual investors collectively own 12.86% of the company.

How big is Artemis Medicare?

As of 24th July, Artemis Medicare Services Ltd has a market capitalization of 3,327.00 Cr, with recent Net Sales of 936.91 Cr and a Net Profit of 82.63 Cr. Shareholder's Funds are 837.68 Cr, and Total Assets are valued at 1,357.41 Cr.

As of 24th July, Artemis Medicare Services Ltd has a market capitalization of 3,327.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 936.91 Cr and a Net Profit of 82.63 Cr.<BR><BR>For the latest annual period, the Shareholder's Funds amounted to 837.68 Cr, while the Total Assets were valued at 1,357.41 Cr.

Is Artemis Medicare overvalued or undervalued?

As of October 16, 2025, Artemis Medicare is considered fairly valued with a PE ratio of 38.36 and a favorable comparison to peers like Apollo Hospitals and Max Healthcare, despite a recent underperformance against the Sensex, but it shows strong long-term growth potential.

As of 16 October 2025, Artemis Medicare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 38.36, an EV to EBITDA of 20.65, and a PEG ratio of 0.72, which suggests a reasonable growth expectation relative to its price.<BR><BR>In comparison to its peers, Artemis Medicare's valuation appears more favorable. For instance, Apollo Hospitals, which is also rated attractive, has a significantly higher PE ratio of 71.71, while Max Healthcare is categorized as very expensive with a PE of 94.88. Despite recent underperformance compared to the Sensex, with a year-to-date return of -23.26% versus the Sensex's 6.82%, Artemis Medicare's strong growth in the long term, as evidenced by a 273.78% return over three years, reinforces its attractiveness in the market.

Are Artemis Medicare latest results good or bad?

Artemis Medicare's Q2 FY26 results are generally positive, with a 40.84% increase in net profit and a 7.74% rise in net sales. However, concerns about low return ratios indicate challenges in capital efficiency, suggesting a cautious outlook for investors.

Artemis Medicare's latest results for Q2 FY26 can be considered good overall, reflecting strong operational momentum. The company reported a net profit of ₹29.97 crores, which is a significant increase of 40.84% compared to the previous quarter. Year-on-year, net profit growth stands at 34.64%. <BR><BR>Additionally, net sales reached ₹274.70 crores, marking a 7.74% increase from the previous quarter and a 13.79% rise year-on-year. The operating margin improved to 18.42%, the highest in eight quarters, indicating better cost management and operational efficiency.<BR><BR>However, there are concerns regarding the company's return ratios, with a return on equity of only 8.11% and return on capital employed at 9.56%, both significantly below industry benchmarks. This raises questions about capital efficiency despite the positive sales and profit growth.<BR><BR>In summary, while Artemis Medicare has shown impressive growth in sales and profits, the underlying issues with return ratios suggest that the company still faces challenges in capital efficiency. Investors may view the results positively, but caution is warranted due to these concerns.

How has been the historical performance of Artemis Medicare?

Artemis Medicare has shown consistent growth, with net sales increasing from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, and profit after tax rising from INR 31.40 crore to INR 82.18 crore during the same period. The company has improved its operating profit margin and cash flow, indicating strong operational efficiency.

Answer:<BR>The historical performance of Artemis Medicare shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Artemis Medicare's net sales have increased significantly from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025. Operating profit (PBDIT) also saw substantial growth, climbing from INR 71.35 crore in March 2022 to INR 184.78 crore in March 2025, with an operating profit margin that improved from 12.16% to 16.2% over the same period. Profit before tax increased from INR 37.18 crore in March 2022 to INR 107.67 crore in March 2025, and profit after tax rose from INR 31.40 crore to INR 82.18 crore. The company's total assets grew from INR 709.66 crore in March 2022 to INR 1,357.41 crore in March 2025, while total liabilities increased from INR 709.66 crore to INR 1,357.41 crore as well. Cash flow from operating activities improved from INR 59 crore in March 2022 to INR 145 crore in March 2025, indicating enhanced operational efficiency. Overall, Artemis Medicare has demonstrated robust growth in sales, profits, and asset base, positioning itself favorably in the market.

Should I buy, sell or hold Artemis Medicare?

Is Artemis Medicare technically bullish or bearish?

As of December 2, 2025, the trend has shifted to bullish with moderate strength, supported by positive indicators like the MACD, RSI, and moving averages, although caution is advised due to some bearish signals on the monthly timeframe.

As of 2 December 2025, the technical trend has changed from mildly bearish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, a bullish RSI on the monthly chart, and bullish signals from moving averages on the daily timeframe. The KST and OBV are also bullish on the weekly timeframe, while the Bollinger Bands show a mildly bullish trend. However, the monthly MACD and KST remain mildly bearish, indicating some caution. Overall, the bullish trend is supported by recent price action, despite a recent decline from the previous close.

Why is Artemis Medicare falling/rising?

As of 03-Dec, Artemis Medicare Services Ltd's stock price is at 271.80, reflecting a decline of 5.53% over the past six days and 13.41% year-to-date, underperforming compared to the Sensex. Despite strong fundamentals, investor interest is waning, as indicated by a 16.49% drop in delivery volume.

As of 03-Dec, Artemis Medicare Services Ltd's stock price is falling, currently at 271.80, which reflects a decrease of 2.15 (-0.78%). The stock has been experiencing a consecutive decline over the past six days, resulting in a total drop of 5.53% during this period. Additionally, the stock's performance over the past week shows a significant decline of 5.20%, while the broader Sensex index has only decreased by 0.59%.<BR><BR>Investor participation has also been declining, with delivery volume on December 2 falling by 16.49% compared to the five-day average, indicating reduced trading interest. Despite the stock trading above its 20-day, 50-day, 100-day, and 200-day moving averages, it is currently below its 5-day moving average, suggesting short-term weakness.<BR><BR>While the company has demonstrated strong fundamentals, such as a low Debt to EBITDA ratio of 1.34 times and healthy growth in operating profit and net profit, these positive factors have not been sufficient to counteract the recent negative sentiment reflected in the stock's price movements. The stock's year-to-date performance shows a decline of 13.41%, contrasting sharply with the Sensex's gain of 8.92%, further indicating the stock's underperformance relative to the market.

Which are the latest news on Artemis Medicare?